Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2005

View Archived Issues

Antagonism of D3 receptors attenuates ethanol consumption in rats / News in Context

Milestone achievements at Inimex releases second tranche of Series A financing

Dade Behring gains rights to combined use of markers in vascular disease

Intercell receives R&D grant to develop biodefense vaccines

Avantogen receives milestone payment from Endocyte

Biota discovers RSV drug candidates

TB Alliance begins clinical trials with PA-824

Phytomedics licenses antiinflammatory compound patent

Advitech completes second study of XP-828L for psoriasis

NGX-4010 enters phase III study for postherpetic neuralgia

Acologix and Toray sign agreement for TRK-820

Somerset submits response for Emsam

Speedel achieves milestone in development of next-generation renin inhibitors

Vical receives HIV vaccine production order to support phase II trials

TLR4 considered a critical therapeutic target for IBD

AL-108 effective in multiple preclinical models of neurotoxicity

Preclinical data on antidiabetic properties of MB-06322; update on development program

New treatments for cancer covered in recent patent literature

Therapeutic benefits of lipid-lowering drugs in transplantation

Antitumor effects found for KOS-953 in relapsed/refractory multiple myeloma

Takeda reports new agents for the treatment of cardiovascular diseases

New data confirm the benefits of tocilizumab in systemic juvenile idiopathic arthritis

Good results found with Bentley's intranasal insulin formulation in type 1 diabetes

Galiximab increases the antitumor efficacy of rituximab in follicular lymphoma

Phase II data supports the use of Sanctura XR for overactive bladder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...